Sol-Gel Technologies (SLGL) Net Income towards Common Stockholders (QoQ) (2018 - 2026)

Sol-Gel Technologies (SLGL) Net Income towards Common Stockholders (QoQ) (2018 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Sol-Gel Technologies 226.64 Mn 216.50 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 106.02%
Dec 31, 2025 -884.65%
Sep 30, 2025 -155.99%
Jun 30, 2025 27.50%
Mar 31, 2025 115.76%
Dec 31, 2024 -6,649.88%
Sep 30, 2024 -150.99%
Jun 30, 2024 -74.40%
Mar 31, 2024 111.90%
Dec 31, 2023 -833.62%
Sep 30, 2023 -195.66%
Jun 30, 2023 -44.31%
Mar 31, 2023 121.06%
Dec 31, 2022 -33,932,666,566.67%
Sep 30, 2022 -100.00%
Jun 30, 2022 -97.61%
Mar 31, 2022 917,540,883.61%
Dec 31, 2021 916.67%
Sep 30, 2021 -100.00%
Jun 30, 2021 97.71%